Both in Biotechnology
Biogen vs Repligen
Over the past year BIIB returned +67.5% and RGEN returned +17.8%; their daily moves had a correlation of 0.15.
BIIB +67.5% RGEN +17.8%Growth of $1, one year, split-adjusted
| Metric | BIIB | RGEN |
|---|---|---|
| Price | $253.62 | $176.94 |
| Market cap | $37.49B | $11.23B |
| Today | +1.59% | −6.20% |
| 1 month | +13.8% | −0.2% |
| 6 months | +35.6% | +51.0% |
| Year to date | +44.1% | +8.0% |
| 1 year | +71.5% | +19.2% |
| Revenue growth (YoY) | +10.6% | +10.9% |
| Gross margin | 73.3% | 53.0% |
| Net margin | −0.7% | −18.4% |
| P/E (TTM) | 107.9× | — |
| Price / sales | 3.6× | 13.9× |
| Net cash | -$6.39B | $307.4M |
| Dividend yield | — | — |
| Volatility (60d) | 27.9% | 47.0% |
| Short % of float | 3.7% | 12.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).